Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Accounts Payables (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Accounts Payables over the past 10 years, most recently at $3.2 million for Q4 2023.

  • For Q4 2023, Accounts Payables rose 46.23% year-over-year to $3.2 million; the TTM value through Dec 2023 reached $3.2 million, up 46.23%, while the annual FY2023 figure was $3.2 million, 46.23% up from the prior year.
  • Accounts Payables for Q4 2023 was $3.2 million at Corbus Pharmaceuticals Holdings, down from $4.7 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $12.7 million in Q2 2020 and troughed at $1.3 million in Q1 2023.
  • A 5-year average of $5.2 million and a median of $3.4 million in 2021 define the central range for Accounts Payables.
  • Biggest five-year swings in Accounts Payables: crashed 85.21% in 2021 and later skyrocketed 243.0% in 2023.
  • Year by year, Accounts Payables stood at $11.1 million in 2019, then crashed by 33.45% to $7.4 million in 2020, then plummeted by 75.85% to $1.8 million in 2021, then increased by 21.98% to $2.2 million in 2022, then skyrocketed by 46.23% to $3.2 million in 2023.
  • Business Quant data shows Accounts Payables for CRBP at $3.2 million in Q4 2023, $4.7 million in Q3 2023, and $1.5 million in Q2 2023.